Compare · GLP-1 agonist
Amycretin vs Mazdutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Amycretin | Mazdutide | |
|---|---|---|
| Evidence | 6/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere. | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. |
| Full profile → | Full profile → |
Amycretin
Amycretin is an experimental drug from Novo Nordisk. Its early weight-loss numbers have turned heads, which is exactly why it keeps popping up on peptide forums and gray-market menus. It is a single molecule (one compound, not a blend) that switches on two receptors at the same time — the GLP-1…
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that switches on two of the body's metabolic hormone receptors at the same time. Most of the buzzy GLP-1 compounds are still stuck at the press-release stage, but mazdutide is further along: it has a full Phase 3 trial published in…